ORION 4 – examining the effects of inclisiran, a small interfering RNA (siRNA) that inhibits the synthesis of PCSK9, on cardiovascular outcomes among individuals with atherosclerotic cardiovascular disease.
CS15 – ISIS 678354-CS15 is a multi-center, open-label study of up to 700 participants with SHTG who would be rolled over from studies ISIS 678354-CS5 CORE or ISIS 678354-CS6 CORE2. The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.
OCEAN(a)-Outcomes (TIMI 75) will evaluate the efficacy and safety of lowering lipoprotein(a) through RNA interference with olpasiran in participants with atherosclerotic cardiovascular disease and elevated lipoprotein(a) concentrations.
LILAC – TIMI 76 is a randomized, double, blind placebo-controlled phase 3 trial investigating the efficacy and safety of the factor XI inhibitor abelacimab in~1,900 patients with AF deemed unsuitable for anticoagulation therapy.
CORALreef Outcomes-TIMI 77 is a phase 3, randomized, placebo-controlled study of the efficacy and safety of MK-0616, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in 14,550 participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of MK-0616 compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent arterial revascularization.
TYDAL-TIMI 78 is a Phase 2B dose-ranging study of MAR001 in adults with elevated triglycerides and remnant cholesterol.
OCEAN(a)-PreEvent (TIMI 79) will evaluate the efficacy and safety of lowering lipoprotein(a) through RNA interference with olpasiran in participants with elevated lipoprotein(a) and at high risk for a first atherosclerotic event.
MARITIME-CV (TIMI 80) is a Phase 3 study for people living with a cardiovascular condition and overweight or obesity.